Navigation Links
Anthera Pharmaceuticals Announces Personnel Changes
Date:6/12/2013

HAYWARD, Calif., June 12, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the appointment of May Liu as its Senior Vice President, Finance and Administration.  In this position, Ms. Liu will oversee the finance, investor relations and general administration functions of Anthera in addition to her role as Principal Accounting Officer.  

"Since the early days of Anthera, Ms. Liu has done an extraordinary job heading up the finance function of Anthera including leading the company through its Initial Public Offering and subsequent fund raising efforts. Ms. Liu has been responsible for the company's planning, accounting and financial reporting functions, and oversees the finance team supporting the R&D and G&A functions.  With 14 years of combined public accounting and industry experience focusing in life science, we know Ms. Liu will continue to be the driving force behind our finance function and look forward to her excelling in her new role," said Paul F. Truex, President and Chief Executive Officer of Anthera. 

Ms. Liu has served as the Company's Vice President, Finance since January 2011.  Prior to that, she served as Anthera's Corporate Controller since October 2007.   Ms. Liu joined the Company as Director of Finance in April 2007.  Prior to that, Ms. Liu served as SEC Reporting and Technical Accounting Manager at Renovis, Inc., a clinical-stage pharmaceutical company, from October 2005 to March 2007.  Ms. Liu has been a Certified Public Accountant since 2007 and was a part of the audit and assurance practice of Ernst & Young, LLP. from 2000 to 2005, focusing primarily in the life science industry.  Ms. Liu holds a B.S. in business administration with a concentration in accounting from San Francisco State University.

Effective June 30th, 2013 Anthera's Chief Business Officer and Chief Financial Officer, Christopher Lowe will leave the company to pursue entrepreneurial opportunities.  "The Board and management of Anthera would like to thank Chris for his years of dedicated service.  Chris's financial leadership and experience have been instrumental in providing funding for Anthera's development programs.  As a result of his efforts we are now well positioned to accomplish our goals with blisibimod over the coming years.  Chris joined us before we became a publicly traded company and was a key part of Anthera's Initial Public Offering, several follow on offerings, and recent debt financings.  We greatly appreciate Chris's efforts and wish him all the best in his future endeavors," said Paul F. Truex. "The Audit Committee of our Board of Directors will continue to provide independent financial oversight."

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about the Company's expectations with respect to its proposed offering, including its intention to offer and sell shares, its intention to grant the underwriters an option to purchase additional shares and its intended use of proceeds from the offering.  Such statements are based on the Company's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as those set forth in the Company's public filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2013.  The Company disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com or 510-856-5598.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Pharmaceuticals to Present at Annual Jefferies Healthcare Conference
2. Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
3. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
4. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
5. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
6. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
7. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
8. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
9. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
10. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
11. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based in ... Parkinson,s disease (PD), has enrolled the first patient in the ... multicenter study involving patients with PD and taking place at ... 9-to-12-month period. The first stage is open label and involves ... include Denver , Boca Raton ...
(Date:5/10/2017)... May 10, 2017 Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended April 1, 2017 ... $1.84 increased 666.7% compared to the prior year period ... in a significant gain, while non-GAAP diluted EPS of ... or 3.8% in constant currency terms.  Excluding the effects ...
(Date:5/10/2017)... Ill. , May 10, 2017 Radiology ... today; unfortunately its costs have also spiraled to the ... being sent to radiology than ever before as the ... diagnosis.  For a patient with lower back pain an ... no anatomical reason for pain, resulting in entirely different ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... 2017 , ... Drs. Nicholas Rallis and Chris Chondrogiannis are ... years as clinical instructors for the reputable Full Mouth Rehabilitation continuing education (CE) ... private practitioners receive cutting-edge clinical training and learn how to perform full ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... Solutions is vehemently opposed to Donald Trump’s budget, “A New Foundation for American ... inspires fear, demonizes the poor, marginalizes underserved populations, undermines productivity, and destroys the ...
(Date:5/24/2017)... Clarkston, Lake Orion, Michigan (PRWEB) , ... ... ... Endometriosis is a disease affecting the female reproductive tract in which the ... on the pelvic structures causing inflammation and pain. Patients experiencing painful intercourse, ...
(Date:5/24/2017)... ... ... you are thinking of a visit to San Francisco , fall is a great ... to visit. , Business Architecture Associates is pleased to offer 5 days of training courses, ... day package for individuals, and as 4-½ day corporate package for up to 3 employees ...
(Date:5/24/2017)... ... May 24, 2017 , ... The CFOs included on this ... systems in the nation and help their organizations navigate the challenges in healthcare ... instrumental in developing successful hospital and health system strategy. , Becker's Hospital Review ...
Breaking Medicine News(10 mins):